FDA-approved
Skin & aging
Ecallantide
Evidence
FDA approved
Class
Kallikrein inhibitor protein
KEY TAKEAWAY
Ecallantide is a 60-amino-acid recombinant protein that inhibits plasma kallikrein. It is sold as Kalbitor. The FDA approved ecallantide (Kalbitor) in 2009 for acute attacks of hereditary angioedema in people 12 and older.
Written by the Veylo editorial team · Updated
November 2026
What it is
Kallikrein inhibitor protein
Approved for
Acute attacks of hereditary angioedema
Key fact
The FDA approved ecallantide (Kalbitor) in 2009 for acute attacks of hereditary angioedema in people 12 and older.
Route
Subcutaneous injection given by a healthcare provider
Evidence strength
FDA approved
Ecallantide is a 60-amino-acid recombinant protein that inhibits plasma kallikrein. It is sold as Kalbitor.
By blocking kallikrein it lowers the production of bradykinin, the molecule that causes swelling during hereditary angioedema attacks.
The FDA approved ecallantide (Kalbitor) in 2009 for acute attacks of hereditary angioedema in people 12 and older.
Acute attacks of hereditary angioedema.
The label carries a boxed warning for serious allergic reactions including anaphylaxis, so a healthcare professional gives it.
U.S. FDA prescribing information for Ecallantide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.